Think of synthetic cannabinoid use in patients with unexplained serious coagulopathy due to possible contamination with long acting vitamin K antagonists. They will need prolonged oral vitamin K treatment, which can challenging due to the cost.

Transfusion of platelets prophylactically may do more harm than good.

Tranexamic acid (TXA) decreased mortality from bleeding in trauma patients.  But there are a few caveats to note.

Compared with vitamin K antagonist (VKA)-related non-traumatic intracerebral hemorrhage (ICH), direct oral anticoagulant (DOAC)-related ICH had less disability, smaller bleeds, and the meta-analysis showed lower in-hospital mortality rates.

A high plasma to PRBC transfusion ratio (>/= 1:2) was not beneficial in pediatric massive trauma transfusion. But this study was different than adult studies of damage control resuscitation in that these children did not receive platelets

Idarucizumab reverses anticoagulation 100% due to dabigatran in the test tube. It seemed to stop active bleeding in patients in about 2.5 hours, and reported operative hemostasis was good.  But since this was an open label trial with no control group, we don't know how the outcomes would have compared with patients who were treated with other procoagulants or who were not treated.

The CISNE score beat the MASCC score for determining which patients with fever and neutropenia may be safe for outpatient management.

NOACs were not associated with an increased risk of traumatic ICH compared to other anticoagulant or antiplatelet agents.

Cancer as a young person increases subsequent risk for cerebrovascular events.  Cancer is in itself a risk factor for stroke.

If a young person presents with chest pain and has had prior treatment for cancer, his or her risk of cardiac disease is far greater than the baseline population.